These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 19739073)

  • 1. Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.
    Símová J; Indrová M; Bieblová J; Mikysková R; Bubeník J; Reinis M
    Int J Cancer; 2010 Jun; 126(12):2997-3004. PubMed ID: 19739073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
    Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
    Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours.
    Símová J; Bubeník J; Bieblová J; Rosalia RA; Fric J; Reinis M
    Int J Oncol; 2006 Dec; 29(6):1567-71. PubMed ID: 17088998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
    Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
    Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically modified cellular vaccines against human papillomavirus type 16 (HPV16)-associated tumors: adjuvant treatment of minimal residual disease after surgery/chemotherapy.
    Bubenik J; Simova J
    J BUON; 2009 Sep; 14 Suppl 1():S169-73. PubMed ID: 19785061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours.
    Reinis M; Símová J; Bubeník J
    Int J Cancer; 2006 Apr; 118(7):1836-42. PubMed ID: 16217768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice.
    Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Yamamoto M; Fujita Y; Miyagi T; Ohkawa K; Hayashi N
    J Hepatol; 2008 Nov; 49(5):779-86. PubMed ID: 18760855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
    Reinis M; Indrová M; Mendoza L; Mikysková R; Bieblová J; Bubeník J; Símová J
    Int J Oncol; 2004 Oct; 25(4):1165-70. PubMed ID: 15375569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.
    Nemeckova S; Smahel M; Hainz P; Mackova J; Zurkova K; Gabriel P; Indrova M; Kutinova L
    Neoplasma; 2007; 54(4):326-33. PubMed ID: 17822323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
    Reinis M; Símová J; Indrová M; Bieblová J; Bubeník J
    Int J Oncol; 2007 May; 30(5):1247-51. PubMed ID: 17390028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy.
    Indrová M; Bieblová J; Rossowska J; Kuropka P; Pajtasz-Piasecka E; Bubeník J; Reinis M
    Int J Oncol; 2009 Jan; 34(1):173-9. PubMed ID: 19082488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
    Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
    Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors.
    Indrová M; Mikysková R; Jandlová T; Vonka V; Bubeník J; Bieblová J
    Folia Biol (Praha); 2003; 49(6):217-22. PubMed ID: 14748435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of γδ T cells in α-galactosylceramide-mediated immunity.
    Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
    J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of whole body hyperthermia with alpha-galactosylceramide in a subcutaneous tumor model of colon cancer.
    Hattori T; Kokura S; Okuda T; Okayama T; Takagi T; Handa O; Naito Y; Yoshida N; Yoshikawa T
    Int J Hyperthermia; 2007 Nov; 23(7):591-8. PubMed ID: 18038289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer.
    Ciavarra RP; Somers KD; Brown RR; Glass WF; Consolvo PJ; Wright GL; Schellhammer PF
    Cancer Res; 2000 Apr; 60(8):2081-4. PubMed ID: 10786663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.